TY - JOUR T1 - PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma – A Pilot Study JF - In Vivo JO - In Vivo SP - 1551 LP - 1554 DO - 10.21873/invivo.11413 VL - 32 IS - 6 AU - SARKA SVOBODOVA AU - MARIE KARLIKOVA AU - ONDREJ TOPOLCAN AU - LADISLAV PECEN AU - MARTINA PESTOVA AU - OTTO KOTT AU - VLADISLAV TRESKA AU - DAVID SLOUKA AU - RADEK KUCERA Y1 - 2018/11/01 UR - http://iv.iiarjournals.org/content/32/6/1551.abstract N2 - Aim: The aim of this study was to evaluate the clinical contribution of protein induced by vitamin K absence (PIVKA-II) for hepatocellular carcinoma (HCC) diagnostics and compare it with alpha-foetoprotein (AFP), a routinely used tumour marker. Materials and Methods: A total of 332 participants were enrolled in this study: 64 with HCC, 48 with liver metastases of colorectal cancer origin, 42 with liver cirrhosis and 178 healthy individuals. Serum levels of PIVKA-II were measured using the chemiluminescent assay of the Architect 1000i System (Abbott, USA) and AFP levels using the chemiluminescent assay by DxI 800 (Beckman Coulter, USA). Results: PIVKA-II achieved better clinical sensitivity than AFP and the difference in this sensitivity was statistically significant. PIVKA-II achieved the best sensitivity (96.9%) in distinguishing between the HCC and control groups with the proposed cut-off value of 60 mAU/ml. Conclusion: Our recommendation is for addition of PIVKA-II to the routine panel of HCC tumour markers. ER -